These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 17904950

  • 21. Effectiveness and safety of daptomycin in complicated skin and soft-tissue infections and bacteraemia in clinical practice: results of a large non-interventional study.
    Gonzalez-Ruiz A, Beiras-Fernandez A, Lehmkuhl H, Dohmen PM, Loeffler J, Chaves RL.
    Int J Antimicrob Agents; 2013 Apr; 41(4):372-8. PubMed ID: 23499225
    [Abstract] [Full Text] [Related]

  • 22. Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE).
    Mohr JF, Friedrich LV, Yankelev S, Lamp KC.
    Int J Antimicrob Agents; 2009 Jun; 33(6):543-8. PubMed ID: 19201165
    [Abstract] [Full Text] [Related]

  • 23. Future directions with daptomycin.
    Livermore DM.
    J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii41-iii49. PubMed ID: 18829725
    [Abstract] [Full Text] [Related]

  • 24. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study.
    Kullar R, Davis SL, Levine DP, Zhao JJ, Crank CW, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ.
    Pharmacotherapy; 2011 Jun; 31(6):527-36. PubMed ID: 21923436
    [Abstract] [Full Text] [Related]

  • 25. Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria.
    Johnson A.
    Future Microbiol; 2006 Oct; 1(3):255-65. PubMed ID: 17661638
    [Abstract] [Full Text] [Related]

  • 26. Multidrug-resistant gram-positive infections in patients with ventricular assist devices: the role of daptomycin.
    Beiras-Fernandez A, Kur F, Kiefer S, Sodian R, Schmoeckel M, Weis M, Reichart B, Weis F.
    Transplant Proc; 2009 Oct; 41(6):2589-91. PubMed ID: 19715980
    [Abstract] [Full Text] [Related]

  • 27. Daptomycin use in patients with cancer and neutropenia: data from a retrospective registry.
    Rolston KV, McConnell SA, Brown J, Lamp KC.
    Clin Adv Hematol Oncol; 2010 Apr; 8(4):249-56, 90. PubMed ID: 20505648
    [Abstract] [Full Text] [Related]

  • 28. Effectiveness and duration of daptomycin therapy in resolving clinical symptoms in the treatment of complicated skin and skin structure infections.
    Krige JE, Lindfield K, Friedrich L, Otradovec C, Martone WJ, Katz DE, Tally F.
    Curr Med Res Opin; 2007 Sep; 23(9):2147-56. PubMed ID: 17669231
    [Abstract] [Full Text] [Related]

  • 29. Linezolid for the treatment of complicated skin and skin structure infections in children.
    Yogev R, Patterson LE, Kaplan SL, Adler S, Morfin MR, Martin A, Edge-Padbury B, Naberhuis-Stehouwer S, Bruss JB.
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S172-7. PubMed ID: 14520143
    [Abstract] [Full Text] [Related]

  • 30. Daptomycin therapy for invasive Gram-positive bacterial infections in children.
    Ardura MI, Mejías A, Katz KS, Revell P, McCracken GH, Sánchez PJ.
    Pediatr Infect Dis J; 2007 Dec; 26(12):1128-32. PubMed ID: 18043450
    [Abstract] [Full Text] [Related]

  • 31. Cubicin Outcomes Registry and Experience (CORE) methodology.
    Rolston KV, Segreti J, Lamp KC, Friedrich LV.
    Am J Med; 2007 Oct; 120(10 Suppl 1):S4-5. PubMed ID: 17904949
    [Abstract] [Full Text] [Related]

  • 32. Daptomycin for the treatment of surgical site infections.
    Chamberlain RS, Culshaw DL, Donovan BJ, Lamp KC.
    Surgery; 2009 Aug; 146(2):316-24. PubMed ID: 19628091
    [Abstract] [Full Text] [Related]

  • 33. [Daptomycin in diabetic patients].
    Montejo M.
    Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():54-8. PubMed ID: 22541977
    [Abstract] [Full Text] [Related]

  • 34. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections.
    Steenbergen JN, Alder J, Thorne GM, Tally FP.
    J Antimicrob Chemother; 2005 Mar; 55(3):283-8. PubMed ID: 15705644
    [Abstract] [Full Text] [Related]

  • 35. Cefdinir vs. cephalexin for mild to moderate uncomplicated skin and skin structure infections in adolescents and adults.
    Giordano PA, Elston D, Akinlade BK, Weber K, Notario GF, Busman TA, Cifaldi M, Nilius AM.
    Curr Med Res Opin; 2006 Dec; 22(12):2419-28. PubMed ID: 17257456
    [Abstract] [Full Text] [Related]

  • 36. [Daptomycin in complicated skin and soft tissue infections].
    Barberán J, Fariñas MC.
    Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():33-7. PubMed ID: 22541973
    [Abstract] [Full Text] [Related]

  • 37. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance.
    Lee SY, Kuti JL, Nicolau DP.
    Surg Infect (Larchmt); 2005 Feb; 6(3):283-95. PubMed ID: 16201938
    [Abstract] [Full Text] [Related]

  • 38. Daptomycin experience in critical care patients: results from a registry.
    Brown JE, Fominaya C, Christensen KJ, McConnell SA, Lamp KC.
    Ann Pharmacother; 2012 Apr; 46(4):495-502. PubMed ID: 22454446
    [Abstract] [Full Text] [Related]

  • 39. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections.
    Lipsky BA, Stoutenburgh U.
    J Antimicrob Chemother; 2005 Feb; 55(2):240-5. PubMed ID: 15659542
    [Abstract] [Full Text] [Related]

  • 40. Daptomycin: rationale and role in the management of skin and soft tissue infections.
    Seaton RA.
    J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii15-23. PubMed ID: 18829721
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.